This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Asgard Therapeutics


Asgard Therapeutics is a private preclinical-stage biotech company pioneering in vivo direct reprogramming for cancer immunotherapy. Since the end of 2021, Asgard is supported by Novo Holdings, Boehringer Ingelheim Venture Fund, and Industrifonden which co-led a €6M Seed round to achieve POC of the lead program. Prior to that, Asgard's scientific founders had been working on the initial proof-of-principle in Lund University supported by €1,5M-worth of European and local non-dilutive grants.

We're bringing you

  • Startup spotlight pitch competition